After rimonabant was pulled for psychiatric side effects, newer cannabinoid strategies including neutral CB1 antagonists, CB2 agonists, and phytocannabinoids like CBD show therapeutic potential for substance use disorders in animal and early human studies.
People interested in addiction treatment research, cannabinoid pharmacology, and the therapeutic potential of the endocannabinoid system.
After rimonabant failure, 7+ new cannabinoid-based addiction treatment strategies are now under study
What the researchers found
Neutral CB1R antagonists (AM4113), CB2R agonists (JWH133, Xie2-64), and phytocannabinoids (CBD, beta-caryophyllene, THCV) show therapeutic potential for SUDs in animals. Clinical trials of dronabinol, nabilone, and the FAAH inhibitor PF-04457845 show promising results for cannabis and opioid withdrawal.
Why it matters
Substance use disorders affect millions with limited treatment options. The endocannabinoid system is deeply involved in reward pathways, making cannabinoid-based drugs logical therapeutic candidates. The field has recovered from the rimonabant setback with more targeted strategies.
The numbers in context
Rimonabant withdrawn from clinical trials worldwide in 2008 due to depression and suicidality. Multiple new strategies now under investigation: peripheral CB1R antagonists, neutral CB1R antagonists, allosteric CB1R modulators, CB2R agonists, FAAH inhibitors, MAGL inhibitors, FABP inhibitors.
How the study worked
Comprehensive review of endocannabinoid system biology, cannabis reward and aversion mechanisms, and cannabinoid-based medication development for substance use disorders, covering preclinical and clinical trial data.
What this study cannot tell us
Most evidence from animal models. Clinical trial data limited to a few compounds. Long-term safety of newer approaches unknown. Translation from animal addiction models to human substance use disorders is historically unreliable.
How to read the evidence
Moderate: comprehensive review covering both preclinical and early clinical data, though most evidence is still from animal models.
When this study was published
Published in 2019.
The bigger picture
The rimonabant failure taught researchers that bluntly blocking CB1 receptors throughout the brain is dangerous. The next generation of cannabinoid therapies is more nuanced, targeting specific receptor subtypes, peripheral locations, or endocannabinoid metabolism rather than the CB1 receptor directly.
Questions still open
- Will peripheral CB1 antagonists avoid the psychiatric risks of rimonabant? Can CBD effectively treat opioid or stimulant addiction in controlled trials? Which specific cannabinoid strategy is most promising for each type of substance use disorder?
Common questions
Can cannabinoids help treat addiction?
What happened with rimonabant?
Read the original research
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
CNS drugs, 33(10), 1001-1030
Citation
Galaj, Ewa; Xi, Zheng-Xiong. (2019). Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.. CNS drugs, 33(10), 1001-1030. https://doi.org/10.1007/s40263-019-00664-w
Explore the wider topic
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Is Rehab Necessary for Weed? An Honest Assessment
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit